Apr 06, 2020
The Global Pulmonary Arterial Hypertension Market is expected to grow from USD 7,196.48 Million in 2019 to USD 9,925.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.50%
Mar 05, 2020
Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class And Segment Forecasts, 2020 - 2027
Jan 15, 2020
Visiongain Publishes Global Pulmonary Arterial Hypertension Market 2019-2029 Report
Sep 30, 2019
Sovateltide (PMZ-1620), an Endothelin-B receptor Agonist, has the potential to be a first-in-class neuronal progenitor cell therapeutics
Jun 27, 2019
Letairis (ambrisentan; Gilead/GlaxoSmithKline) Market to 2025: A Selective Endothelin Type A Receptor Antagonist
Jun 26, 2019
Opsumit Drug Profile 2016-2025: Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku) is Set to Become the Market Leader with Forecast Peak Sales of $2.2bn in 2025
Jun 26, 2019
Tracleer (bosentan; Johnson & Johnson) Drug Overview & Product Profiles 2016-2025
Feb 07, 2019
Results on Efficacy of PMZ-1620, an Endothelin-B Agonist, from Ongoing Phase II Trial in Patients with Cerebral Ischemic Stroke Presented at International Stroke Conference 2019
Jun 18, 2018
Pulmonary Arterial Hypertension Treatment Market is Expected to Reach CAGR of 2.5% Over the Forecast Period 2018-2028- Future Market Insights
Apr 10, 2018
Pulmonary Arterial Hypertension (PAH) Market Size Anticipated to Reach $8.7 Billion by 2025 | Million Insights
Oct 24, 2017
Bayer to Present Pulmonary Arterial Hypertension Data at the 2017 Annual Meeting of the American College of Chest Physicians
Sep 06, 2017
Actelion Receives FDA Approval Of TRACLEER® (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Jun 29, 2017
Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers